1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Sun Shines On Biotech Stocks As J.P. Morgan Ends

Deal Activity Kept Key Indices Rising

 
• By Mandy Jackson

Public Company Edition: Also, Johnson & Johnson’s consumer health spin-out Kenvue filed paperwork to get the ball rolling on an initial public offering. In addition, Geron raised $198m and Madrigal accessed more than $300m after positive trial readouts, but layoffs were revealed by Editas, Elevation, Nabriva and others.

Finance Watch Public Company
• Source: Alamy

The sun shined on the first and last days of the J.P. Morgan Healthcare Conference, held 9-12 January in San Francisco, and the rain, winds and downed trees that soaked and blocked the paths of the meeting’s attendees did not serve as a metaphor for the performance of biotechnology stocks during the annual week during which companies, investors and other market observers try to forecast what the year ahead will be like for the biopharmaceutical industry.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

In Brief: Synthetic Design Lab Debuts With $20m To Advance Cutting-Edge ADCs

 
• By Sushmita Panda

As ADCs continue to be a growth area globally, a new US-based venture with novel platform technology has emerged from stealth mode with $20m in funding.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

Alis Biosciences Launches To Free Cash From Stalled-Out Biotechs

 
• By Mandy Jackson

As investors have begun to ask troubled drug developers to suspend operations and return remaining cash to shareholders, Alis has stepped forward with a new fund aiming to facilitate that.

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down

 
• By Mandy Jackson

Restructuring Edition: ESSA and Elevation are reviewing strategic alternatives after trial failures, but each has an investor urging them to liquidate. Also, Third Harmonic and Vincerx are winding down, while Keros and Tempest are assessing options, but Opthea and OPM are cutting jobs.

More from Business

Regeneron To Expand US Manufacturing, Citing Commercial And Clinical Expansion

 
• By Alaric DeArment

The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.

Enzene Sees Tariff Exemptions For India, Front-Ends US Capacity

 
• By Vibha Ravi

Enzene's CEO Himanshu Gadgil anticipates exemptions for Indian products from US tariffs expected to be imposed on pharmaceuticals. In an interview ahead of the US Vice Premier's India visit, he also talks about front-loading capacity at Enzene's US plant and a change in its biosimilars strategy

Stock Watch: Dollar Weakness, Tariffs, Biosimilars In J&J’s Q1 Mix

 
• By Andy Smith

Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.